SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today announced that it will be presenting Phase 1/2 data on mocetinostat in myelodysplastic syndromes (MDS) at the 55 th American Society of Hematology Annual Meeting taking place December 7-10 in New Orleans. Data to be presented demonstrates promising clinical responses to the combination of mocetinostat, a novel spectrum selective HDAC inhibitor, with azacitidine (marketed as Vidaza® by Celgene) in patients with MDS. The abstract is currently available online at https://ash.confex.com/ash/2013/webprogram/Paper64121.html.
Title: Combination Therapy With Mocetinostat, An Oral, Spectrum-Selective Histone Deacetylase (HDAC) Inhibitor, and 5-Azaciditine: Indication Of Clinical Activity In MDS
Session Name: 633. Myelodysplastic Syndromes: Poster IDate: Saturday, December 7, 2013Presentation Time: 5:30 PM - 7:30 PMLocation: Ernest N. Memorial Convention Center, Hall EAbout MocetinostatMocetinostat is an inhibitor of Class I HDACs currently in development for the treatment of patients with intermediate 2 and high-risk myelodysplastic syndromes (MDS). Mocetinostat has been studied in 13 clinical trials including 437 patients and the combination of mocetinostat and azacitidine showed a 93 percent disease control rate in 28 patients with MDS. Plans are underway for initiation of a Phase 3 trial of mocetinostat in combination with azacitidine in first line MDS patients in the second half of 2014. In addition, Mirati is exploring additional opportunities for mocetinostat in patients with lymphoma in whom the drug has demonstrated encouraging preliminary evidence of clinical activity. About Mirati TherapeuticsMirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations. Mirati's approach combines the three most important factors in oncology drug development - drug candidates with complementary and compelling targets, creative and agile clinical development, and a highly accomplished precision medicine leadership team. The Mirati team is using its proven blueprint for developing targeted oncology medicines to advance and maximize the value of its pipeline of drug candidates, including MGCD265 and MGCD516, which are orally bioavailable, multi-targeted kinase inhibitors with distinct target profiles, and mocetinostat, an orally bio-available, spectrum-selective histone deacetylase inibitor. More information is available at www.mirati.com. Forward-Looking StatementsCertain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking information and forward-looking statements (collectively "forward-looking statements" within the meaning of applicable securities laws). Such statements, based as they are on the current expectations of management of Mirati and upon what management believes to be reasonable assumptions based on information currently available to it, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Mirati's control. Such statements can usually be identified by the use of words such as "may", "would", "believe", "intend", "plan", "anticipate", "estimate" and other similar terminology, or state that certain actions, events or results "may" or "would" be taken, occur or be achieved. Forward-looking statements in this release include, but are not limited to, statements regarding the promise of clinical responses to mocetinostat in combination with 5-azacitidine, and the timing of an initiation of a Phase 3 trial of mocetinostat. Whether actual results and developments will conform with the expectations and predictions contained in this news release is subject to a number of risks, assumptions and uncertainties, many of which are beyond Mirati's control, and the effects of which can be difficult to predict. These risks include, but are not limited to, those inherent in drug development, market risks and uncertainties, unexpected cash requirements or changes in Mirati's business plans and other risks described in Mirati's filings with the Securities and Exchange Commission. In evaluating any forward-looking statements in this release, Mirati cautions readers not to place undue reliance on any forward-looking statements. Unless otherwise required by applicable securities laws, Mirati does not intend, nor does it undertake any obligation, to update or revise any forward-looking statements contained in this news release to reflect subsequent information, events, results or circumstances or otherwise.